# Pieris

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pieris

- Industry: Pharmaceuticals
- Headquarters: Freising, Germany
- Website: www.pieris-ag.com
- Total disclosed funding: $66M
- Latest round: Series E (Nov 26, 2014)
- Investors on record: 11

## About

Founded in 2001, Pieris AG, a biopharmaceutical company engages in the discovery and development of targeted protein therapeutics for the diagnosis and treatment of severe human disorders.

## Funding rounds

- Series E, Nov 26, 2014, $8.2M — OrbiMed Advisors, Global Life Science Ventures, BioM, Gilde Healthcare, BayTech Venture Capital, Ally Bridge Group
- Series B, Mar 27, 2008, $40M — OrbiMed Advisors, Global Life Science Ventures, Gilde Healthcare, Forbion, Novo Nordisk A/S
- Series A, Nov 1, 2006, $6.4M — AAC Capital Partners, Global Life Science Ventures, BioM, Gilde Healthcare, BayTech Venture Capital
- Series A, Oct 31, 2002, $12M — Global Life Science Ventures, BioM, Gilde Healthcare, BayTech Venture Capital, Capital A, TransConnect

## Investors

- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series A, Series B, Series E
- BioM (https://capitalatlas.ai/funds/biom) — Series A, Series E
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series B, Series E
- BayTech Venture Capital (https://capitalatlas.ai/funds/baytech-venture-capital) — Series A, Series E
- Capital A — Series A
- TransConnect (https://capitalatlas.ai/funds/transconnect) — Series A
- AAC Capital Partners (https://capitalatlas.ai/funds/aac-capital-partners) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series E
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Novo Nordisk A/S — Series B
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series E